Newsfeeds Archive - Page 2 of 4

4 minute read

Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

May 22, 1:20 PM

Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.

ABSI

2 minute read

VectivBio Holding, Greenhill, Atea Pharmaceuticals And Other Big Stocks Moving Higher On Monday

By Lisa Levin

May 22, 10:31 AM

U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Friday. Here are some big stocks recording gains in today’s session. Greenhill & Co., Inc. (NYSE: GHL) shares rose 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.

AVIR

3 minute read

US Stocks Mixed; Nordic American Tankers Posts Upbeat Results

By Lisa Levin

May 22, 9:50 AM

U.S. stocks traded mixed this morning, with the Dow Jones trading slightly lower on Monday. Following the market opening Monday, the Dow traded down 0.01% to 33,422.94 while the NASDAQ rose 0.09% to 12,669.27. The S&P 500, also rose, gaining, 0.08% to 4,195.41.

AVIR

13 minute read

Earnings

Earnings Scheduled For May 8, 2023

By Benzinga Insights

May 8, 9:03 AM

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.

ACAD

1 minute read

Earnings

Earnings Preview: Atea Pharmaceuticals

By Benzinga Insights

May 5, 3:01 PM

Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Monday, 2023-05-08. Here’s what investors…

AVIR

31 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

March 24, 12:05 PM

On Friday, 469 companies hit new 52-week lows.

AAIC

1 minute read

JP Morgan Maintains Neutral on Atea Pharmaceuticals, Lowers Price Target to $8

By Benzinga Newsdesk

March 16, 8:46 AM

JP Morgan analyst Eric Joseph maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Neutral and lowers the price target from $12 to $8.

AVIR

1 minute read

Atea Pharmaceuticals Announced The Presentation Of New Phase 1, In Vitro And In Vivo Data That Demonstrate Key Profile Attributes Of Atea’s Lead Drug Candidate, Bemnifosbuvir, For Covid-19 And Hepatitis C

By Benzinga Newsdesk

March 14, 7:18 AM

Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern evaluated as well as

AVIR